Marie Florescu

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

Benjamin Besse, Elvire Pons‐Tostivint, Keunchil Park et al. · Nature Medicine · 2024 · 116 citations · Full text

Medicine, Oncology, Pharmacology +17

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial

Quincy S. Chu, Laurent Greillier, Wei Tu et al. · The Lancet · 2023 · 101 citations

Medicine, Oncology, Pharmacology +15

Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre study

Antoine Desîlets, Félix Blanc‐Durand, Sally C. M. Lau et al. · European Journal of Cancer · 2020 · 78 citations

Medicine, Oncology, Radiation Oncology +14

Mutations in NSCLC and their link with lung cancer-associated thrombosis: A case-control study

Luis Corrales, Denis Soulières, Xiaoduan Weng et al. · Thrombosis Research · 2013 · 59 citations · Full text

Medicine, Genetics, Oncology +13

Economic Analysis of NCIC CTG JBR.10: A Randomized Trial of Adjuvant Vinorelbine Plus Cisplatin Compared With Observation in Early Stage Non–Small-Cell Lung Cancer—A Report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group

Raymond Ng, Baktiar Hasan, Nicole Mittmann et al. · Journal of Clinical Oncology · 2007 · 53 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17